Checkpoint Therapeutics (CKPT) Lifted to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Checkpoint Therapeutics (NASDAQ:CKPT) from a hold rating to a buy rating in a report released on Friday. The brokerage currently has $4.50 price target on the stock.

According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “

Separately, HC Wainwright assumed coverage on Checkpoint Therapeutics in a report on Friday, December 8th. They issued a buy rating and a $11.00 price objective for the company.

Shares of Checkpoint Therapeutics (NASDAQ CKPT) opened at $4.65 on Friday. The company has a market capitalization of $118.99 and a P/E ratio of -4.15. Checkpoint Therapeutics has a twelve month low of $3.20 and a twelve month high of $15.00.

WARNING: This piece was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2018/01/22/checkpoint-therapeutics-ckpt-lifted-to-buy-at-zacks-investment-research.html.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.

Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply